ResMed Inc (STU:RME)
€ 232.3 -1.9 (-0.81%) Market Cap: 34.52 Bil Enterprise Value: 34.92 Bil PE Ratio: 32.70 PB Ratio: 6.98 GF Score: 98/100

Resmed Inc at Citi Healthcare Conference (Virtual) Transcript

Feb 23, 2022 / 05:30PM GMT
Release Date Price: €209.2 (+3.31%)
Joanne Karen Wuensch
Citigroup Inc., Research Division - MD

Good afternoon, everybody, or good morning or good evening, depending on where you are. My name is Joanne Wuensch. I'm the U.S. medical technology analyst. Very pleased to have with us today CEO, Mick Farrell from ResMed. As many of you know, ResMed is covered by our Australian analyst John Deakin-Bell. Today, I'm the moderator. So let's just get started.

Questions & Answers

Joanne Karen Wuensch
Citigroup Inc., Research Division - MD

Mick, the industry is dominated - commentary, at least - is dominated currently by the Philips device recall. In John's memory, this is about a 3.5 million units, which are recalled, and a key question to start off this discussion is how are the customers coping? And how are the physicians coping with this impact?

Michael J. Farrell
ResMed Inc. - CEO & Director

Yes. Well, I believe the latest data, Joanne, is -- John was right about 2 months ago. I think our competitor updated it to 5.2 million devices that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot